PE20181449A1 - Compuestos utiles como inhibidores de cinasa - Google Patents

Compuestos utiles como inhibidores de cinasa

Info

Publication number
PE20181449A1
PE20181449A1 PE2018001143A PE2018001143A PE20181449A1 PE 20181449 A1 PE20181449 A1 PE 20181449A1 PE 2018001143 A PE2018001143 A PE 2018001143A PE 2018001143 A PE2018001143 A PE 2018001143A PE 20181449 A1 PE20181449 A1 PE 20181449A1
Authority
PE
Peru
Prior art keywords
alkyl
substituted
tyrosine kinase
group selected
kinase inhibitors
Prior art date
Application number
PE2018001143A
Other languages
English (en)
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of PE20181449A1 publication Critical patent/PE20181449A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Referido a compuesto de formula (I), o sus sales farmaceuticamente aceptables; en donde A es un anillo seleccionado a partir de sustituido o no sustituido: fenilo, piridina, piridazina, entre otros; R1 es un grupo seleccionado a partir de: alquilo C1-8, haloalquilo C1-8, entre otros; R2 es un grupo seleccionado a partir de: -OH, halo, alquilo C1-8, entre otros; R3 es -C(O)NRERF, alquiloC1-6 sustituido con haloalquiloC1-6, entre otros; R4a y R4b son, independientemente, H, alquilo C1-6, haloalquiloC1-6, entre otros; R5 es H o alquilo C1-4; R6 es un grupo seleccionado a partir de un sustituido o no sustituido: fenilo o un anillo heteroarilo de 5 o 6 elementos, entre otros. Estos compuestos son inhibidores de tirosina cinasa, especificamente, de la tirosina cinasa de Bruton (BTK). Tambien se refiere a metodos para tratar condiciones tratables por la inhibicion de la tirosina cinasa de Bruton, por ejemplo, cancer, linfoma, leucemia, enfermedades inmunologicas, entre otras.
PE2018001143A 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa PE20181449A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20181449A1 true PE20181449A1 (es) 2018-09-12

Family

ID=57590725

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2021001581A PE20220507A1 (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa
PE2018001143A PE20181449A1 (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa
PE2021001592A PE20220502A1 (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2021001581A PE20220507A1 (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021001592A PE20220502A1 (es) 2015-12-16 2016-12-16 Compuestos utiles como inhibidores de cinasa

Country Status (35)

Country Link
US (7) US10695323B2 (es)
EP (2) EP3390395B1 (es)
JP (3) JP6731483B2 (es)
KR (2) KR102215792B1 (es)
CN (9) CN114573510A (es)
AU (4) AU2016373530B2 (es)
CA (1) CA3008488C (es)
CL (1) CL2018001591A1 (es)
CO (1) CO2018006164A2 (es)
CR (1) CR20180367A (es)
CY (1) CY1123561T1 (es)
DK (1) DK3390395T3 (es)
EA (1) EA035132B1 (es)
ES (1) ES2828431T3 (es)
FI (1) FIC20240004I1 (es)
HK (1) HK1263254A1 (es)
HR (1) HRP20201835T1 (es)
HU (2) HUE051921T2 (es)
IL (4) IL285976B2 (es)
LT (1) LT3390395T (es)
MA (2) MA49809A1 (es)
MD (1) MD3390395T2 (es)
MX (2) MX2018007267A (es)
NL (1) NL301262I2 (es)
NZ (1) NZ743553A (es)
PE (3) PE20220507A1 (es)
PH (1) PH12018501268A1 (es)
PT (1) PT3390395T (es)
RS (1) RS60982B1 (es)
SG (2) SG11201805044WA (es)
SI (1) SI3390395T1 (es)
TN (1) TN2018000213A1 (es)
UA (2) UA127863C2 (es)
WO (1) WO2017103611A1 (es)
ZA (4) ZA201804137B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
EP3390395B1 (en) 2015-12-16 2020-09-09 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
KR20210028144A (ko) * 2018-04-06 2021-03-11 블랙 벨트 티엑스 리미티드 Atf6 저해제 및 그의 용도
WO2019220962A1 (ja) * 2018-05-18 2019-11-21 富士フイルム株式会社 ３－ジフルオロメチルピラゾール化合物の製造方法及び３－ジフルオロメチルピラゾール－４－カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物
CA3108065A1 (en) * 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20220273593A1 (en) * 2019-09-19 2022-09-01 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
CA3160417A1 (en) * 2019-12-06 2021-06-10 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
WO2021180107A1 (en) * 2020-03-12 2021-09-16 Fochon Pharmaceuticals, Ltd. Compounds useful as kinase inhibitors
TWI809489B (zh) 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
WO2022240920A1 (en) 2021-05-14 2022-11-17 Loxo Oncology, Inc. Cocrystalline forms of a bruton's tyrosine kinase inhibitor
KR20240029070A (ko) * 2021-07-01 2024-03-05 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
WO2023174397A1 (en) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376A (zh) * 2022-12-15 2023-04-04 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212327T3 (da) 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
EP2068869A4 (en) * 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
WO2010010154A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN107021951B (zh) * 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
PL2710007T3 (pl) 2011-05-17 2020-06-01 The Regents Of The University Of California Inhibitory kinazy
BR112013028846B1 (pt) 2011-05-17 2021-12-07 Principia Biopharma Inc Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150291554A1 (en) * 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
SG11201602070TA (en) * 2013-09-30 2016-04-28 Beijing Synercare Pharma Tech Co Ltd Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
MX2016010754A (es) 2014-02-21 2017-03-03 Principia Biopharma Inc Sales y forma solida de un inhibidor btk.
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
EP3250567B1 (en) 2015-01-28 2019-10-30 Bayer Pharma Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6728382B2 (ja) 2015-12-16 2020-07-22 エコラブ ユーエスエイ インク 膜濾過浄化のためのペルオキシギ酸組成物
CA3008648C (en) 2015-12-16 2023-01-10 Priostar Pty Ltd Dendrimer and formulations thereof
EP3390395B1 (en) 2015-12-16 2020-09-09 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
PL3390390T3 (pl) 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych
WO2017106396A1 (en) 2015-12-16 2017-06-22 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Also Published As

Publication number Publication date
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
JP2020172535A (ja) 2020-10-22
KR102215792B1 (ko) 2021-02-16
CA3008488C (en) 2023-10-10
ES2828431T3 (es) 2021-05-26
CY1123561T1 (el) 2022-03-24
MX2021003478A (es) 2022-07-25
AU2021225162B2 (en) 2023-08-03
FIC20240004I1 (fi) 2024-03-01
WO2017103611A1 (en) 2017-06-22
ZA201804137B (en) 2022-08-31
MX2018007267A (es) 2018-11-09
CN108473481B (zh) 2022-04-19
IL276283B (en) 2021-03-25
US10464905B2 (en) 2019-11-05
CN114621146A (zh) 2022-06-14
CN114573510A (zh) 2022-06-03
NL301262I2 (nl) 2024-04-24
US20190000806A1 (en) 2019-01-03
EP3782994A1 (en) 2021-02-24
EA201891268A1 (ru) 2018-11-30
CL2018001591A1 (es) 2018-09-28
EA035132B1 (ru) 2020-04-30
EP3390395B1 (en) 2020-09-09
IL281067A (en) 2021-04-29
IL259923A (en) 2018-07-31
BR112018012341A2 (pt) 2018-12-04
ZA202100544B (en) 2023-06-28
ZA202107471B (en) 2023-03-29
SG10202012498TA (en) 2021-01-28
PH12018501268A1 (en) 2019-02-18
PE20220502A1 (es) 2022-04-07
RS60982B1 (sr) 2020-11-30
NZ743553A (en) 2022-08-26
IL285976A (en) 2021-10-31
CN114716381A (zh) 2022-07-08
UA122258C2 (uk) 2020-10-12
PE20220507A1 (es) 2022-04-07
JP2022120013A (ja) 2022-08-17
JP2018538307A (ja) 2018-12-27
HUS2400003I1 (hu) 2024-03-28
SG11201805044WA (en) 2018-07-30
SI3390395T1 (sl) 2020-11-30
HK1263254A1 (zh) 2020-02-21
HUE051921T2 (hu) 2021-03-29
US20190135762A1 (en) 2019-05-09
JP7419437B2 (ja) 2024-01-22
CN108473481A (zh) 2018-08-31
AU2021201811B2 (en) 2022-01-27
IL285976B1 (en) 2023-06-01
IL285976B2 (en) 2023-10-01
US20230372298A1 (en) 2023-11-23
IL259923B (en) 2020-08-31
CN114605327A (zh) 2022-06-10
AU2021201811A1 (en) 2021-04-22
US11826351B2 (en) 2023-11-28
JP7086140B2 (ja) 2022-06-17
MA55064A (fr) 2021-09-29
IL281067B (en) 2022-04-01
CO2018006164A2 (es) 2018-09-20
CN113603645A (zh) 2021-11-05
AU2016373530B2 (en) 2021-01-21
AU2021225161B2 (en) 2023-08-03
US10342780B2 (en) 2019-07-09
CA3008488A1 (en) 2017-06-22
US10918622B2 (en) 2021-02-16
AU2021225162A1 (en) 2021-09-30
AU2021225161A1 (en) 2021-09-30
CR20180367A (es) 2018-11-12
AU2016373530A1 (en) 2018-07-05
US20200276162A1 (en) 2020-09-03
US11471441B2 (en) 2022-10-18
US20180362512A1 (en) 2018-12-20
CN114634447A (zh) 2022-06-17
MD3390395T2 (ro) 2021-02-28
CN113636978A (zh) 2021-11-12
KR20210018530A (ko) 2021-02-17
IL276283A (en) 2020-09-30
MA49809A1 (fr) 2021-08-31
TN2018000213A1 (en) 2019-10-04
DK3390395T3 (da) 2020-09-28
EP3390395A1 (en) 2018-10-24
UA127863C2 (uk) 2024-01-31
US20210093611A1 (en) 2021-04-01
CN114591242A (zh) 2022-06-07
KR20180115261A (ko) 2018-10-22
LT3390395T (lt) 2020-11-25
HRP20201835T1 (hr) 2021-01-08
US20220062239A1 (en) 2022-03-03
ZA202107472B (en) 2023-03-29
JP6731483B2 (ja) 2020-07-29

Similar Documents

Publication Publication Date Title
PE20181449A1 (es) Compuestos utiles como inhibidores de cinasa
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
PH12019501222A1 (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
PE20190437A1 (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
MX2018004347A (es) Compuestos utiles como inmunomoduladores.
CU24265B1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
PE20160995A1 (es) Inhibidores de syk
NZ708909A (en) Substituted reverse pyrimidine bmi-1 inhibitors
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
PE20170203A1 (es) Derivados de nucleosido sustituidos con 4'-difluorometilo como inhibidores de la replicacion de arn de la influeza
PE20190979A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
AR115015A1 (es) Derivados de azaespiro piperazina
EA201692189A1 (ru) Соединения фосфина золота (i) в качестве антибактериальных агентов
EA201692190A1 (ru) Соединения фосфина золота (i) в качестве антибактериальных агентов
AR106047A1 (es) Derivado de biarilo y medicamento que contiene el mismo para el tratamiento de infecciones fúngicas